Journal of Prevention and Treatment for Stomatological Diseases ›› 2021, Vol. 29 ›› Issue (1): 40-44.DOI: 10.12016/j.issn.2096-1456.2021.01.006

• Cinical Study • Previous Articles     Next Articles

Evaluation of the efficacy of cevimeline in improving the clinical symptoms of patients with primary Sjögren′s syndrome

WANG Shengming1(),LI Fangfang2(),WU Yao1,SHI Xinlian1,LIU Xin3   

  1. 1. Department of Stomatology, the Affiliated Huai′an Hospital of Xuzhou Medical University, Huai′an 223001, China
    2. Department of Ophthalmology, the Affiliated Huai′an Hospital of Xuzhou Medical University, Huai′an 223001, China
    3. Department of Rheumatology, the Affiliated Huai′an Hospital of Xuzhou Medical University, Huai′an 223001, China
  • Received:2020-04-14 Revised:2020-07-20 Online:2021-01-20 Published:2020-11-18
  • Contact: Fangfang LI



  1. 1.徐州医科大学附属淮安医院口腔科,江苏 淮安(223001)
    2.徐州医科大学附属淮安医院眼科,江苏 淮安(223001)
    3.徐州医科大学附属淮安医院风湿科,江苏 淮安(223001)
  • 通讯作者: 李芳芳
  • 作者简介:汪声明,主治医师,硕士,Email:


Objective To investigate the clinical efficacy of cevimeline as a pharmacotherapeutic approach to stimulating gland activity in improving the symptoms and signs of primary Sj?gren syndrome (pSS). Methods Sixty-three patients diagnosed with pSS who attended the Affiliated Huai'an Hospital of Xuzhou Medical University from January 2018 to September 2019 were included in this trial. They were randomly assigned to the therapeutic group and control group. All patients were recalled at baseline and after 2 weeks, 3 months and 6 months. Measurement of salivary and lacrimal flow as well as evaluation of subjective symptoms was performed at the follow-up. Results Fifty-eight patients completed the trial and were included in the statistical analysis. There was a significant difference between the two groups in the measurement of salivary and lacrimal flow at the second week and third month (P < 0.05). Improvement in subjective symptoms of oral, ocular and gland was detected at the third month (P < 0.05). At the sixth month, compared with the control group, only the salivary gland symptom score of the treatment group was statistically significant (P < 0.05). Conclusion Cevimeline has good specificity and safety and can increase salivary and lacrimal flow and improve subjective symptoms of pSS in a short time.

Key words: cevimeline, Sj?gren′s syndrome, autoimmune disease, gland secretion, improving symptoms, salivary secretion, lacrimal secretion, visual analog scale


目的 探讨西维美林应用于原发性舍格伦综合征(primary Sj?gren syndrome,pSS)患者的临床疗效,为pSS的治疗提供新的思路。方法 纳入2018年1月至2019年9月在徐州医科大学附属淮安医院被诊断为pSS的患者63例,随机分入治疗组和对照组,治疗组给予西维美林,对照组给予安慰剂,服用3周后,在第2周,第3、6个月复诊,复诊时测定患者唾液、泪液分泌量以及主观症状改善情况。结果 共有58患者完成试验并纳入统计,患者在第2周和第3个月复诊时,治疗组唾液、泪液分泌量高于对照组,且差异有统计学意义(P < 0.05)。主观症状方面,第3个月复诊时,口腔、眼部与唾液腺症状均有所改善(P < 0.05),而第6个月复诊时,与对照组相比,治疗组仅唾液腺症状评分具有统计学意义(P < 0.05)。结论 西维美林具有良好的特异性和安全性,能够在短期内增加唾液、泪液分泌,对改善pSS临床症状具有良好的疗效。

关键词: 西维美林, 舍格伦综合征, 自身免疫病, 腺体分泌, 症状改善, 唾液分泌, 泪液分泌, 视觉模拟评分

CLC Number: